Brought to you by 
Astellas, Medivation, NanoString team up in companion diagnostics deal
10 Feb 2016
Executive Summary
NanoString Technologies Inc. entered into a collaboration with Medivation Inc. and Astellas Pharma Inc. to translate a gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString's nCounter Dx analysis system.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas, Medivation, NanoString team up in companion diagnostics deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice